As HGG-MYCN often carry both alterations, MYCN amplifications and TP53 mutations, we generated a mouse model with combined expression of wild-type human MYCN and a loss of Trp53, which, on its own, induces glioma development in mice with a long latency and reduced penetrance33. This evidence concerns the gene TP53 and central nervous system cancer.